Dai ichi Life Insurance Company Ltd Reduces Position in Becton, Dickinson and Company (NYSE:BDX)

Dai ichi Life Insurance Company Ltd reduced its stake in Becton, Dickinson and Company (NYSE:BDXFree Report) by 9.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 26,358 shares of the medical instruments supplier’s stock after selling 2,828 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Becton, Dickinson and Company were worth $6,427,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Mendel Money Management increased its position in shares of Becton, Dickinson and Company by 3.0% in the 3rd quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock valued at $397,000 after purchasing an additional 45 shares during the last quarter. CWM LLC boosted its stake in Becton, Dickinson and Company by 0.7% during the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after purchasing an additional 46 shares during the period. S.A. Mason LLC boosted its stake in Becton, Dickinson and Company by 3.5% during the 4th quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock worth $346,000 after purchasing an additional 48 shares during the period. Mitchell Mcleod Pugh & Williams Inc. boosted its stake in Becton, Dickinson and Company by 1.3% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,951 shares of the medical instruments supplier’s stock worth $963,000 after purchasing an additional 49 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its stake in Becton, Dickinson and Company by 1.4% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 3,604 shares of the medical instruments supplier’s stock worth $932,000 after purchasing an additional 50 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Barclays increased their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $281.40.

Check Out Our Latest Stock Analysis on Becton, Dickinson and Company

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,597 shares of company stock worth $2,028,786. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded up $1.07 during mid-day trading on Wednesday, hitting $235.93. 352,970 shares of the company’s stock traded hands, compared to its average volume of 1,402,997. The company has a market cap of $68.19 billion, a PE ratio of 51.73, a price-to-earnings-growth ratio of 2.08 and a beta of 0.45. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The firm’s 50 day simple moving average is $238.04 and its 200 day simple moving average is $238.63.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the company earned $2.86 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.